Cardiac Biomarkers: Technologies and Global Markets

1
Cardiac Biomarkers Technologies and Global
Markets
One-Stop Shop for Business Information
2
Summary
The global market for in vitro diagnostic tests
for cardiac biomarkers was estimated at 3.1
billion in 2012 and nearly 4 billion in 2013.
This market is predicted to reach 7.2 billion by
2018, at a compound annual growth rate (CAGR) of
12.8 over the five-year period from 2013 to
2018.This report provides -An overview of the
global market for biomarkers for cardiovascular
disease (CVD) and related technologies. -Analyses
of global market trends, with data from 2012,
estimates for 2013, and projections of CAGRs for
the period 2013 to 2018. -Classification of CVD
by cerebrovascular, congestive, coronary,
hypertensive, and peripheral arterial
disease. -Background and clinical values of
cardiac biomarkers, including B-type natriuretic
peptide (BNP), N-terminal pro-B-type natriuretic
peptide
3
(NT-proBNP), C-reactive protein (CRP), choline,
creatine kinase MB (CK-MB), D-dimer, glial
fibrillary acidic protein (GFAP), heart fatty
acid binding protein (H-FABP), ischemia-modified
albumin (IMA), myeloperoxidase (MPO), myoglobin,
soluble fragment CD40 ligand (sCD40L), and
troponin I (cTnI)/troponin T (cTnT). -Examination
of the technology covering diagnostic methods,
instrumentation, newly issued patents, and new
patent applications.-Clinical guidelines and
government regulations. This report provides a
comprehensive analysis of the cardiac biomarker
market and its trends from 2012 through 2018. It
details the history and current state of
cardiovascular diseases (CVDs), background on
cardiac biomarkers and the current industrial
technologies for their diagnosis. An in-depth
analysis is provided of the predominant
biomarkers in the market, namely,
4

• Current and projected forecasts assay revenues
  during the forecast period (2013 to 2018) are
  presented. In addition, newly developed assays
  with regulatory approval and others expected to
  receive FDA approval within the forecast period
  are also projected. Figures for 2013 are
  estimated, except where actual results have been
  reported, due to the timing of the release of the
  report. For large market segments, such as
  cardiac troponin and natriuretic peptides, the
  analytical sensitivities and cutoff references
  for the diagnosis and prognosis values are
  discussed in detail. Moreover, the ongoing effort
  in developing a high-sensitivity troponin assay,
  as well as the attempt to pursue additional
  biomarkers for the diagnosis of congestive heart
  failure and strokes are focused on in this study.
• The report includes an analysis of leading and
  emerging competitors in the current worldwide
  diagnostics market for cardiovascular diseases.

5
This report is intended for business consultants,
acquisitions specialists, licensing strategists,
product managers, market research analysts,
investors, investor consultants and anyone who is
interested in the cardiac biomarker market, its
products, its industry participants and its
future. The importance of identifying overall
market trends, product opportunities, emerging
geographic markets, MA opportunities and
insights that provide guidance for sales growth
or defensive moves cannot be overstated for a
variety of constituents, including
6
Table Of Content

• Chapter- 1 INTRODUCTION - Complimentary 4 0
• Chapter- 2 SUMMARY 2 250
• Chapter- 3 OVERVIEW 35 4156
• Chapter- 4 INDUSTRY STRUCTURE AND COMPETITIVE
  ANALYSIS
• 15 1781
• Chapter- 5 MARKET BY ASSAY 1 119
• Chapter- 6 MARKET BY INSTRUMENT 4 475
• Chapter- 7 MARKET BY REGION 11 1306

7

• To know more
• Cardiac Biomarkers Technologies and Global
  Markets

Contact Us-Call India 91-22-27810772/73 Call
USA/Canada (Toll Free) 1-866-279-8368 Email id
info_at_bharatbook.com